Literature DB >> 34170696

Indium(III)-Catalyzed Stereoselective Synthesis of Tricyclic Frameworks by Cascade Cycloisomerization Reactions of Aryl 1,5-Enynes.

Ramón E Millán1, Jaime Rodríguez1, Luis A Sarandeses1, Enrique Gómez-Bengoa2, José Pérez Sestelo1.   

Abstract

The indium(III)-catalyzed cascade cycloisomerization reaction of 1,5-enynes with pendant aryl nucleophiles is reported. The reaction proceeds in cascade under mild reaction conditions, using InI3 (5 mol %) as a catalyst with a range of 1,5-enynes furnished with aryl groups (phenyl and phenol) at alkene (E and Z isomers) and with terminal and internal alkynes. Using 1-bromo-1,5-enynes, a one-pot sequential indium-catalyzed cycloisomerization and palladium-catalyzed cross-coupling with triorganoindium reagents were developed. The double cyclization is stereospecific and operates via a biomimetic cascade cation-olefin through 1,5-enyne cyclization (6-endo-dig) and subsequent C-C hydroarylation or C-O phenoxycyclization. Density functional theory (DFT) computational studies on 1,5-enynyl aryl ethers support a two-step mechanism where the first stereoselective 1,5-enyne cyclization produces a nonclassical carbocation intermediate that evolves to the tricyclic reaction product through a SEAr mechanism. Using this approach, a variety of tricyclic heterocycles such as benzo[b]chromenes, phenanthridines, xanthenes, and spiroheterocyclic compounds are efficiently synthesized with high atom economy.

Entities:  

Year:  2021        PMID: 34170696     DOI: 10.1021/acs.joc.1c00825

Source DB:  PubMed          Journal:  J Org Chem        ISSN: 0022-3263            Impact factor:   4.354


  1 in total

1.  Antimicrobial Diterpene Alkaloids from an Agelas citrina Sponge Collected in the Yucatán Peninsula.

Authors:  Dawrin Pech-Puch; Abel M Forero; Juan Carlos Fuentes-Monteverde; Cristina Lasarte-Monterrubio; Marta Martinez-Guitian; Carlos González-Salas; Sergio Guillén-Hernández; Harold Villegas-Hernández; Alejandro Beceiro; Christian Griesinger; Jaime Rodríguez; Carlos Jiménez
Journal:  Mar Drugs       Date:  2022-04-28       Impact factor: 6.085

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.